Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril

Abstract Background and objectives The study investigated the intravitreal safety and vitreous disposition of lisinopril, an angiotensin converting enzyme inhibitor in rabbits for its projected use in retinopathy. Methods For the safety study, following the baseline ERG recording and fundus photogra...

Full description

Bibliographic Details
Main Authors: Madhu Nath, Nabanita Halder, Parijat Chandra, Sundararajan Baskar Singh, Ashok Kumar Deorari, Atul Kumar, Thirumurthy Velpandian
Format: Article
Language:English
Published: BMC 2018-11-01
Series:International Journal of Retina and Vitreous
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40942-018-0146-7
id doaj-2a72df83f5c549b1b8fa5d21e0cb94eb
record_format Article
spelling doaj-2a72df83f5c549b1b8fa5d21e0cb94eb2021-04-02T09:17:11ZengBMCInternational Journal of Retina and Vitreous2056-99202018-11-01411810.1186/s40942-018-0146-7Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinoprilMadhu Nath0Nabanita Halder1Parijat Chandra2Sundararajan Baskar Singh3Ashok Kumar Deorari4Atul Kumar5Thirumurthy Velpandian6Department of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical SciencesOcular Pharmacology and Pharmacy Division, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical SciencesDepartment of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical SciencesDepartment of Biophysics, All India Institute of Medical SciencesDepartment of Neonatal Intensive Care Unit, Pediatrics, All India Institute of Medical SciencesDepartment of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical SciencesOcular Pharmacology and Pharmacy Division, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical SciencesAbstract Background and objectives The study investigated the intravitreal safety and vitreous disposition of lisinopril, an angiotensin converting enzyme inhibitor in rabbits for its projected use in retinopathy. Methods For the safety study, following the baseline ERG recording and fundus photography, 40 µg/50 µl of lisinopril sterile injection was injected unilaterally in the rabbit eyes (n = 4), where other eye served as a control. The electroretinogram and fundus images were obtained at 24, 48, 72 and 168 h following the intravitreal injection. For pharmacokinetics evaluation of the lisinopril, one eye of each rabbit (n = 4) received an intravitreal injection of lisinopril (40 µg/50 µl). The concentration of lisinopril in the ocular tissues, humours, plasma, lung, kidney and liver were measured through ESI-LC-MS/MS. Results Upon the electroretinography studies, no significant difference was observed in the ERG pattern in the lisinopril injected eye when compared to the baseline of the respective animals till the 7th day of the study. In the fundus imaging, no morphological changes were observed in the retina of the animal. The concentration of the lisinopril was found to be above to the IC50 in the retina-choroid till 36 h. The concentration found in the plasma and body tissues were many folds less than the IC50 of the lisinopril. Conclusions Intravitreal injection of 40 µg/50 µl of lisinopril found to be safe in the rabbit eye as evidenced by the electroretinography and fundus imaging studies. The average half-life of lisinopril is 12.6 h and the above-mentioned dose able to sustain its IC50 value till the 36 h.http://link.springer.com/article/10.1186/s40942-018-0146-7LisinoprilIntravitreal injectionOcular safetyElectroretinographyPharmacokinetics
collection DOAJ
language English
format Article
sources DOAJ
author Madhu Nath
Nabanita Halder
Parijat Chandra
Sundararajan Baskar Singh
Ashok Kumar Deorari
Atul Kumar
Thirumurthy Velpandian
spellingShingle Madhu Nath
Nabanita Halder
Parijat Chandra
Sundararajan Baskar Singh
Ashok Kumar Deorari
Atul Kumar
Thirumurthy Velpandian
Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril
International Journal of Retina and Vitreous
Lisinopril
Intravitreal injection
Ocular safety
Electroretinography
Pharmacokinetics
author_facet Madhu Nath
Nabanita Halder
Parijat Chandra
Sundararajan Baskar Singh
Ashok Kumar Deorari
Atul Kumar
Thirumurthy Velpandian
author_sort Madhu Nath
title Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril
title_short Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril
title_full Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril
title_fullStr Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril
title_full_unstemmed Ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril
title_sort ocular kinetics and safety of intravitreally injected angiotensin converting enzyme inhibitor lisinopril
publisher BMC
series International Journal of Retina and Vitreous
issn 2056-9920
publishDate 2018-11-01
description Abstract Background and objectives The study investigated the intravitreal safety and vitreous disposition of lisinopril, an angiotensin converting enzyme inhibitor in rabbits for its projected use in retinopathy. Methods For the safety study, following the baseline ERG recording and fundus photography, 40 µg/50 µl of lisinopril sterile injection was injected unilaterally in the rabbit eyes (n = 4), where other eye served as a control. The electroretinogram and fundus images were obtained at 24, 48, 72 and 168 h following the intravitreal injection. For pharmacokinetics evaluation of the lisinopril, one eye of each rabbit (n = 4) received an intravitreal injection of lisinopril (40 µg/50 µl). The concentration of lisinopril in the ocular tissues, humours, plasma, lung, kidney and liver were measured through ESI-LC-MS/MS. Results Upon the electroretinography studies, no significant difference was observed in the ERG pattern in the lisinopril injected eye when compared to the baseline of the respective animals till the 7th day of the study. In the fundus imaging, no morphological changes were observed in the retina of the animal. The concentration of the lisinopril was found to be above to the IC50 in the retina-choroid till 36 h. The concentration found in the plasma and body tissues were many folds less than the IC50 of the lisinopril. Conclusions Intravitreal injection of 40 µg/50 µl of lisinopril found to be safe in the rabbit eye as evidenced by the electroretinography and fundus imaging studies. The average half-life of lisinopril is 12.6 h and the above-mentioned dose able to sustain its IC50 value till the 36 h.
topic Lisinopril
Intravitreal injection
Ocular safety
Electroretinography
Pharmacokinetics
url http://link.springer.com/article/10.1186/s40942-018-0146-7
work_keys_str_mv AT madhunath ocularkineticsandsafetyofintravitreallyinjectedangiotensinconvertingenzymeinhibitorlisinopril
AT nabanitahalder ocularkineticsandsafetyofintravitreallyinjectedangiotensinconvertingenzymeinhibitorlisinopril
AT parijatchandra ocularkineticsandsafetyofintravitreallyinjectedangiotensinconvertingenzymeinhibitorlisinopril
AT sundararajanbaskarsingh ocularkineticsandsafetyofintravitreallyinjectedangiotensinconvertingenzymeinhibitorlisinopril
AT ashokkumardeorari ocularkineticsandsafetyofintravitreallyinjectedangiotensinconvertingenzymeinhibitorlisinopril
AT atulkumar ocularkineticsandsafetyofintravitreallyinjectedangiotensinconvertingenzymeinhibitorlisinopril
AT thirumurthyvelpandian ocularkineticsandsafetyofintravitreallyinjectedangiotensinconvertingenzymeinhibitorlisinopril
_version_ 1724169722285522944